Amgen profits rise, next MariTide studies start by mid-year
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a hold on an early-stage trial of a different experimental weight-loss drug.
Pipeline Problems Mar Amgen’s Q4 Beat
Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 and the discontinuation of other programs.
Amgen Surpasses Q4 Earnings Forecasts
Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.
Amgen Inc. Q4 Profit Decreases, But Beats Estimates
Amgen Inc. (AMGN) reported a profit for fourth quarter that decreased from the same period last year but beat the Street estimates.
Amgen: Q4 Earnings Snapshot
The average estimate of 13 analysts surveyed by Zacks Investment Research was for earnings of $5.03 per share. The world's largest biotech drugmaker posted revenue of $9.09 billion in the period, also beating Street forecasts.
Compared to Estimates, Amgen (AMGN) Q4 Earnings: A Look at Key Metrics
Amgen (AMGN) reported $9.09 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 10.9%. EPS of $5.31 for the same period compares to $4.71 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $8.
Amgen Q4 Earnings: Good Quarter, Ok Guidance, But MariTide Concerns Me (Rating Downgrade)
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Investor's Business Daily on MSN22h
Amgen Shrugs Off A Surprise Setback For One Of Its Obesity Drugs
Amgen stock rose early Wednesday, though the biotech behemoth said the FDA placed one of its obesity treatments on clinical ...
FierceBiotech1d
Amgen's early-stage obesity asset slapped with FDA hold
Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial ...
Amgen Q4 Earnings: Strong Pipeline And Label Expansions Justify Buy Rating
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
STAT1d
Study of Amgen’s early obesity candidate paused by FDA
The company said the agency's hold was "not related to the drug,” dubbed AMG 513, and that discussions were underway to ...
Amgen Inc (AMGN) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Expansions
Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, ...
The Motley Fool: An inside look at Amgen’s fall
Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...
Amgen says Phase 1 AMG 513 obesity study placed on clinical hold by FDA
Amgen (AMGN) provided updates on selected product and pipeline programs, including that a Phase 1 study of AMG 513 in people living with ...
STAT1d
Pharmalittle: We’re reading about an FDA hold on an Amgen obesity drug, imported Canadian drugs, and more
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.